An Introduction to Myelodysplastic Syndromes
Myelodysplastic syndromes include a range of bone marrow malignancies characterised by cytopenia and ineffective haematopoiesis, resulting in chronic anaemia and the risk of progression to acute myeloid leukaemia. The current standard of care ranges from supportive care to allogeneic stem cell transplant until recently, progress had lagged behind other blood cancers, with no new approved therapies in over a decade. However, in July 2020 the FDA approved the first oral treatment, a fixed-dose combination of the hypomethylating agent decitabine and the cytidine deaminase inhibitor cedazuridine. Luspatercept-aamt has also recently been approved for treatments in patients with anaemia who require red blood cell transfusions and have not achieved success with an erythropoiesis-stimulating agent.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Myelodysplastic Syndromes Content
Nicolaus Kröger, ASH 2018 – Treatment of Myelodysplastic Syndrome in Elderly Patients
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to donor availability in elderly patients with myelodysplastic syndrome. Questions: 1. What are the […]
ASH 2016 Naval Daver Interview
Dr Naval Daver discusses the use of nivolimumab and ipilimumab in combination with azacitidine in myelodysplastic syndrome and acute myeloid leukemia. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Transient Elastography for the Detection of Hepatic Iron Overload in Patients with Myelodysplastic Syndrome
European Oncology & Haematology, 2016;12(2):103–6 DOI: https://doi.org/10.17925/EOH.2016.12.02.103
In myelodysplastic syndrome (MDS), iron overload (IOL) is the result of multiple red blood cell (RBC) transfusions and increased iron absorption. The cause for the latter is low hepcidin levels due to an ineffective erythropoiesis.1 Increased iron absorption contributes to IOL, but chronic RBC transfusions are considered the main cause of IOL.2 IOL can lead […]
Myelodysplastic Syndromes – The Epigenetic Model for Drug Development?
European Oncology & Haematology, 2016;12(1):13–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.13
Epigenetic dysregulation in myelodysplastic syndromes – how important is it? Our understanding of the biology and pathogenesis of myelodysplastic syndromes (MDS) has evolved dramatically in the last two decades. Evidence of an epigenetic background of the disease identified by a hypermethylation of specific genes and promoter-associated CpG islands was reported in the late 1990s1and first […]
Myelodysplastic Syndromes – Just a Matter of Age?
Oncology & Hematology Review, 2016;12(1):20–1 DOI: https://doi.org/10.17925/OHR.2016.12.01.20
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematologic disorders, characterized by inefficient hematopoiesis, myeloid dysplasia, and an increased risk for developing acute myeloid leukemia (AML).1,2 In the majority of patients, morbidity and mortality are the result of progressive cytopenias, but transformation to AML is observed in approximately one-third of patients. MDS is […]
Lenalidomide – A Brief Review of its Use in Myelodysplastic Syndromes
European Oncology & Haematology, 2015;11(2):141–6 DOI: https://doi.org/10.17925/EOH.2015.11.02.141
Myelodysplastic Syndromes and 5q Deletion Myelodysplastic syndromes (MDS) are a group of rare blood disorders that occur as a result of abnormal development of blood cells within the bone marrow. MDS may progress to life-threatening failure of the bone marrow or develop into an acute leukaemia. It affects, most commonly, the elderly population, with median […]
Combination therapy for high-risk MDS
Adding a second agent to azacitidine for older patients with high-risk myelodysplastic syndrome (MDS) was not found to improve outcomes in the North American Intergroup MDS study, according to Dr Sekeres (Cleveland Clinic, Cleveland, USA) who talked to ecancertv at ASH 2014 about this phase II randomised trial.
Efficacy of Azacitidine in Different MDS Subgroups
Dr. Valeria Santini expounds upon how to understand the efficacy of azacitidine in different myelodysplastic syndromes’ (MDS) subgroups.
Important MDS research at ASH 2014
Dr. Benjamin Ebert of Brigham and Women’s Hospital and a member of the AA&MDSIF Medical Advisory Board, discusses the most important research about MDS (myelodysplastic syndromes) reported at the 2014 American Society of Hematology Annual Meeting. Highlights include genetic mutations and targeting new treatment therapies. Low risk MDS clinical trials are discussed and bone marrow […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!